Altimmune (NASDAQ:ALT) Shares Down 5.1% – Time to Sell?

Shares of Altimmune, Inc. (NASDAQ:ALT) were down 5.1% on Tuesday . The company traded as low as $8.52 and last traded at $8.54. Approximately 316,980 shares changed hands during trading, a decline of 92% from the average daily volume of 3,820,236 shares. The stock had previously closed at $9.00.

Analyst Upgrades and Downgrades

ALT has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, November 14th. UBS Group initiated coverage on shares of Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target on the stock. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Altimmune Trading Down 6.2 %

The firm has a market cap of $600.30 million, a price-to-earnings ratio of -5.40 and a beta of 0.15. The stock has a fifty day moving average price of $7.77 and a 200 day moving average price of $7.08.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. The business had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period in the prior year, the business earned ($0.39) earnings per share. On average, sell-side analysts forecast that Altimmune, Inc. will post -1.36 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ALT. B. Riley Wealth Advisors Inc. grew its position in Altimmune by 12.9% in the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock valued at $144,000 after acquiring an additional 2,687 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Altimmune in the third quarter worth about $674,000. Barclays PLC increased its stake in Altimmune by 93.0% during the third quarter. Barclays PLC now owns 155,741 shares of the company’s stock valued at $956,000 after acquiring an additional 75,064 shares during the period. Geode Capital Management LLC grew its stake in shares of Altimmune by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after purchasing an additional 74,194 shares during the period. Finally, Wellington Management Group LLP lifted its position in Altimmune by 27.5% during the 3rd quarter. Wellington Management Group LLP now owns 197,232 shares of the company’s stock valued at $1,211,000 after purchasing an additional 42,553 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.